Sana Biotechnology (SANA) H.C. Wainwright 26th Annual Global Investment Conference 2024 summary

Platform overview and clinical programs

• Hypoimmune platform aims to overcome allogeneic rejection in cell therapies for oncology, autoimmune diseases, and Type 1 diabetes.

• Four clinical programs target seven indications, with additional pipeline work in CNS disorders.

• Key clinical trials include SC291 (CD19 CAR T), SC262 (CD22 CAR T), and UP421 (islet cell therapy).

Scientific approach and technology

• Hypoimmune cells are engineered by disrupting MHC class I/II and overexpressing CD47 to evade both adaptive and innate immunity.

• Preclinical models in mice and primates show immune evasion and function.

• Published results in top journals validate the approach.

Clinical trial progress and early data

• SC291 in blood cancers shows no dose-limiting toxicity, no graft-versus-host disease, and early efficacy with ongoing complete responses.

• SC262 targets CD19 CAR T failures in blood cancers, addressing a high unmet need with a phase I trial underway.

• SC291 is also being tested in autoimmune diseases (lupus nephritis, extrarenal lupus, AAV) with the GLEAM trial, leveraging scalable manufacturing.